Results 321 to 330 of about 185,125 (388)

Anti-reflux mucosectomy for proton pump inhibitor refractory gastroesophageal reflux disease with hiatal hernia: A case report. [PDF]

Medicine (Baltimore)
Ba Y, Liu S, Shi N, Chen Y, Xu H.
europepmc   +1 more source

CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 loss‐of‐function (LOF) alleles decrease the antiplatelet effect of clopidogrel following percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndrome (ACS). The impact of genotype in patients undergoing PCI for stable ischemic heart disease (SIHD) in real‐world populations is less clear.
Catherine Chanfreau‐Coffinier, Kevin A. Friede, Mary E. Plomondon, Kyung Min Lee, Zhenyu Lu, Tia Dinatale, Scott L. DuVall, Jason L. Vassy, Stephen W. Waldo, John H. Cleator, Thomas M. Maddox, Daniel J. Rader, Themistocles L. Assimes, Scott M. Damrauer, Philip S. Tsao, Kyong‐Mi Chang, Deepak Voora, Julie A. Lynch, Jay Giri, VA Million Veteran Program, Sony Tuteja   +20 more
wiley   +1 more source

Over-the-counter (OTC) H2-receptor antagonists (H2RA) do not compromise the intragastric pH control with proton pump inhibitors (PPI's)

, 2001
Radu Țuțuian, Philip O. Katz, Fawzia Ahmad, Madhu Pamaganamamula, Maria Dipietro, Danald O. Castell   +5 more
openalex   +1 more source

Link between pharyngeal acid reflux episodes and the effectiveness of proton pump inhibitor therapy. [PDF]

World J Gastroenterol
Chen YY, Wang CC, Chuang CY, Tsou YA, Peng YC, Chang CS, Lien HC.   +6 more
europepmc   +1 more source

Insights Into Patient‐Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline

Clinical Pharmacology &Therapeutics, EarlyView.
This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes.
Bella D. Ianni, Chin Hang Yiu, Mohammad A. Ali, Christine Y. Lu   +3 more
wiley   +1 more source

Proton pump inhibitor-induced large gastric polyps can regress within 2 months after discontinuation: Experience from two cases. [PDF]

DEN Open
Inaba T, Yamauchi K, Ishikawa S, Colvin HS, Izumikawa K, Yamamoto K, Takahashi S, Wato M, Nakamura S, Kawano S.   +9 more
europepmc   +1 more source

Learning Strategies from Nature's Blueprint to Cyclic Carbonate Synthesis

ChemSusChem, Volume 18, Issue 6, March 15, 2025.
The development of sustainable synthetic methods for cyclic carbonates draws inspiration from nature, focusing on eco‐friendly processes and renewable resources like CO2 and biomass. This review explore various CO2 activation mechanisms, green chemistry principles, and green catalysts.
Erika Saccullo, Vincenzo Patamia, Chiara Zagni, Antonio Rescifina, Giuseppe Floresta   +4 more
wiley   +1 more source

Dual Therapies Containing an Antibiotic Plus a Proton Pump Inhibitor or Vonoprazan for <i>Helicobacter pylori</i> Infection: A Systematic Review. [PDF]

Microorganisms
Shih CA, Wu DC, Shie CB, Hsu PI.
europepmc   +1 more source

Analytical and Pharmacological Characterization of 1‐(Furan‐2‐Carbonyl)‐LSD (1F‐LSD) and Comparison With 1‐(Thiophene‐2‐Carbonyl)‐LSD (1T‐LSD)

Drug Testing and Analysis, EarlyView.
The novel lysergamide 1‐(furan‐2‐carbonyl)‐LSD (1F‐LSD) was analytically characterized. 1F‐LSD showed LSD‐like activity in vivo similar to 1‐(thiophene‐2‐carbonyl)‐LSD (1T‐LSD) used for comparison. Administration studies in mice and LC–MS analysis revealed that 1F‐LSD served as a prodrug.
Simon D. Brandt, Pierce V. Kavanagh, Sarah Gare, Simon P. Elliott, Alexander Stratford, Adam L. Halberstadt   +5 more
wiley   +1 more source

Impact of Proton Pump Inhibitor Use on Progression-Free and Overall Survival in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis of Recent Studies. [PDF]

Cancers (Basel)
Ciappina G, Ottaiano A, Santorsola M, Esposito E, De Luca F, Giorgi C, Zito C, Capra AP, Carroccio P, Maurea N, Quagliariello V, Campo I, Passalacqua MI, Incognito D, Cacciola I, Consolo P, Berretta M.   +16 more
europepmc   +1 more source